Lutris Pharma Ltd.
๐ฎ๐ฑIsrael
- Country
- ๐ฎ๐ฑIsrael
- Ownership
- Holding
- Established
- 2015-12-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.lutris-pharma.com
LUT014 for the Reduction of Dose-Limiting Acneiform Lesions Associated With EGFRI Treatment of mCRC
Phase 2
Recruiting
- Conditions
- EGFRI Induced Acneiform Lesions
- Interventions
- Drug: LUT014 Gel (Dose 2)Drug: PlaceboDrug: LUT014 Gel (Dose 1)
- First Posted Date
- 2021-02-18
- Last Posted Date
- 2023-10-06
- Lead Sponsor
- Lutris Pharma Ltd.
- Target Recruit Count
- 117
- Registration Number
- NCT04759664
- Locations
- ๐บ๐ธ
UCLA, Santa Monica, California, United States
๐บ๐ธWillis-Knighton Cancer Center, Shreveport, Louisiana, United States
๐บ๐ธFox Chase Cancer Center, Philadelphia, Pennsylvania, United States
LUT014 for the Treatment of Radiation Induced Dermatitis in Breast Cancer Patients
Phase 1
Completed
- Conditions
- Radiation Dermatitis
- Interventions
- Drug: LUT014 GelDrug: Placebo for LUT014 Gel
- First Posted Date
- 2020-02-07
- Last Posted Date
- 2022-07-27
- Lead Sponsor
- Lutris Pharma Ltd.
- Target Recruit Count
- 28
- Registration Number
- NCT04261387
- Locations
- ๐บ๐ธ
Willis-Knighton Cancer Center, Shreveport, Louisiana, United States
๐บ๐ธColumbus Regional Research Institute, Llc, Columbus, Georgia, United States
A Study of LUT014 in Patients With Metastatic Colorectal Cancer With EGFR Inhibitor Induced Acneiform Lesions
- First Posted Date
- 2019-03-15
- Last Posted Date
- 2022-04-06
- Lead Sponsor
- Lutris Pharma Ltd.
- Target Recruit Count
- 10
- Registration Number
- NCT03876106
- Locations
- ๐บ๐ธ
MD Anderson Cancer Center, Houston, Texas, United States
๐บ๐ธUCLA Health Santa Monica - Cancer Care, Los Angeles, California, United States
๐บ๐ธMemorial Sloan Kettering Cancer Center, New York, New York, United States
ยฉ Copyright 2025. All Rights Reserved by MedPath